XNCR: Xencor Corp Net earnings per share (EPS TTM)

Xencor (XNCR) - corporate logo

Xencor, Inc. offsets its R&D costs through licensing fees from partners. The trailing 12-month EPS reflects profitability trends, while -1.60 indicates the current level of the metric. Geopolitical tensions and sanctions hinder the export of oncology drugs, complicating global trials. The business model relies on outsourcing production and testing via CRO/CMO to reduce capital expenditures.

XNCR Xencor, Inc. Net earnings per share for the last 12 months (07/04/2022 - 11/15/2026)

Summary analytical data breakdowns for Xencor Inc. (XNCR)

- share price and expert price forecast:
- market capitalization information:
Fundamental valuation:XNCR - Xencor Inc.
Flagship merchandise of Xencor Corp

This indicator measures the real equity value of the business by dividing the aggregate net income over the last four quarters by the total number of shares to determine the actual earnings per share. By analyzing the rolling annual earnings per share, an investor can assess the monetization efficiency of the Xencor, Inc. (XNCR) antibody platform within the immuno-oncology segment, which confirms the fundamental stability of the asset.

Main competitors

IBRX: Net earnings per share for the last 12 months|Earnings per share for the trailing year IMCR (Immunocore)|JANX: Net earnings per share (EPS TTM)|RCUS - Net earnings per share for the last four quarters|Earnings per share for the last twelve months zymeworks.com|Net earnings per share for the last 12 months tangotx.com (TNGX)|Earnings per share for the last twelve months Iovance Biotherapeutics Inc (IOVA)|Net earnings per share for the last 12 months Immatics Corp IMTX|Compass Therapeutics Inc - Net earnings per share for the last 12 months|Net earnings per share (EPS TTM) Replimune Inc. REPL|LYEL - Earnings per share for the last twelve months|IPHA (innate-pharma.com) - Earnings per share for the last 12 months|pyxisoncology.com (PYXS) - Earnings per share for the last twelve months|Net earnings per one share for the last twelve months Compugen Ltd. (CGEN)|Net earnings per share for the last 12 months IOBT|STRO - Net earnings per share for the trailing year|Net earnings per share for the last 12 months INKT (MiNK)|Earnings per share for the last four quarters HOWL|Net earnings per share (EPS TTM) IMMX (Immix Biopharma, Inc.)|Earnings per share for the trailing year ALXO|CUE - Earnings per share for the last twelve months|Net earnings per one share for the last twelve months PDS Biotechnology Corporation|Sonnet BioTherapeutics Holdings Inc. (SONN) - Earnings per share for the last twelve months|MAIA Biotechnology - Earnings per share for the trailing year|LIMN (liminatuspharma.com) - Net earnings per share (EPS TTM)|Net earnings per share (EPS TTM) lavatherapeutics.com|Earnings per share for the last twelve months NextCure (NXTC)|LPTX: Earnings per one share for the last 12 months|Intensity Therapeutics, Inc. - Net earnings per share for the last 12 months|Sensei Biotherapeutics (SNSE) - Net earnings per one share for the last twelve months|TOVX: Net earnings per share for the last 12 months|Net earnings per share for the trailing year Gritstone bio (GRTS)|KA: Net earnings per share (EPS TTM)|Net earnings per one share for the last twelve months NexImmune, Inc. (NEXI)|Earnings per share for the last twelve months turnstonebio.com|Net earnings per share for the last 12 months Vaccinex, Inc. (VCNX)|Earnings per share for the last twelve months Harpoon Therapeutics (HARP)